Cequent Pharmaceuticals
Cequent is a biopharmaceutical company pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed Cequent Pharmaceuticals Information
Cequent Pharmaceuticals was acquired by
Marina Biotech.
The acquisition happend on 2010-04-01.
Details of the transaction were not public
Acquirer
Geographic Data
Address:
City: Cambridge
State: Massachusetts
Zip:
Country: United States
Financial Info
Stage:
series b
Raised Last:
$3M
Raised Total:$12M
Social
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
An early-stage biopharmaceutical company, Cequent is pioneering the development of novel therapeutics to prevent and treat a wide range of human diseases – from inflammatory diseases to cancer – based on the company&s;s proprietary technology, TransKingdom RNA interference (tkRNAi). Cequent&s;s first products, now in pre-clinical development, are drug candidates targeting colon-cancer prevention and inflammatory bowel disease. The company designed its powerful tkRNAi technology to deactivate specific disease-causing genes safely and effectively, using non-pathogenic bacteria as an engine to produce and deliver RNAi directly into cells. It is based on ground-breaking scientific research originating at the Institut Pasteur (Paris, France) and at the Beth Israel Deaconess Medical Center/Harvard Medical School. A privately held company based in Cambridge, Massachusetts, Cequent was established in 2006. In July 2010, Cequent Pharmaceuticals was acquired by Marina Biotech, Inc (formerly MDRNA, Inc) for $46M.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 6/2007 | Series A | 4 | $9M |
Novartis Venture Fund Nexus Medical Partners Ampersand Capital Partners Pappas Ventures Novartis Venture Fund Novartis Venture Fund Nexus Medical Partners Ampersand Capital Partners Pappas Ventures Novartis Venture Fund |
10/2009 | Series B | $3.4M |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
